Hepatitis Monthly

Published by: Kowsar

Are Women With Polycystic Ovarian Syndrome at a High Risk of Non-Alcoholic Fatty Liver Disease; A Meta-Analysis

Mahdi Ramezani-Binabaj 1 , 2 , Mohsen Motalebi 3 , * , Hamidreza Karimi-sari 1 , Mohammad Saeid Rezaee-Zavareh 1 , 2 and Seyed Moayed Alavian 2
Authors Information
1 Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
3 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: November 2014, 14 (11); e23235
  • Published Online: November 1, 2014
  • Article Type: Review Article
  • Received: September 4, 2014
  • Revised: September 21, 2014
  • Accepted: October 8, 2014
  • DOI: 10.5812/hepatmon.23235

To Cite: Ramezani-Binabaj M, Motalebi M, Karimi-sari H, Rezaee-Zavareh M S, Alavian S M. et al. Are Women With Polycystic Ovarian Syndrome at a High Risk of Non-Alcoholic Fatty Liver Disease; A Meta-Analysis, Hepat Mon. 2014 ;14(11):e23235. doi: 10.5812/hepatmon.23235.

Abstract
Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
Footnote
References
  • 1. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007; 47(3): 412-7[DOI][PubMed]
  • 2. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010; 25(1): 212-20[DOI][PubMed]
  • 3. Saki F, Karamizadeh Z. Metabolic syndrome, insulin resistance and Fatty liver in obese Iranian children. Iran Red Crescent Med J. 2014; 16(5)[DOI][PubMed]
  • 4. Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci. 2013; 6(1): 9-14[DOI][PubMed]
  • 5. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011; 33(7): 801-14[DOI][PubMed]
  • 6. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107(5): 450-5[PubMed]
  • 7. Lahsaee S, Ghazizade A, Yazdanpanah M, Enhesari A, Malekzadeh R. Assessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman. Gastroenterol Hepatol Bed Bench. 2012; 5(4): 183-9[PubMed]
  • 8. Zueff LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012; 39(3): 341-7[DOI][PubMed]
  • 9. FAISAL A, GADALLAH AN, ZYITON A, ESKANDER A. Liver Affection in Polycystic Ovary Syndrome (PCOS).
  • 10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50(8): 1844-50[PubMed]
  • 11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4(10)[DOI][PubMed]
  • 12. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006; 86 Suppl 1-8[DOI][PubMed]
  • 13. Zheng RH, Ding CF. [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study]. Zhonghua Fu Chan Ke Za Zhi. 2008; 43(2): 98-101[PubMed]
  • 14. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des. 2010; 16(17): 1941-51[PubMed]
  • 15. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006; 40 Suppl 1-10[DOI][PubMed]
  • 16. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16(4): 347-63[DOI][PubMed]
  • 17. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis. 2006; 185(2): 227-39[DOI][PubMed]
  • 18. Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract. 2008; 62(9): 1337-43[DOI][PubMed]
  • 19. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol. 2009; 24(2): 243-7[DOI][PubMed]
  • 20. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G, et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest. 2009; 32(8): 695-700[DOI][PubMed]
  • 21. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010; 9(4): 402-9[PubMed]
  • 22. Qu Z, Zhu Y, Jiang J, Shi Y, Chen Z. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med. 2013; 11(9): 725-32[PubMed]
  • 23. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007; 5(4): 496-501[DOI][PubMed]
  • 24. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J. 2004; 147(1): 106-12[PubMed]
  • 25. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142(8): 611-9[PubMed]
  • 26. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007; 65(6 Pt 2)-63[PubMed]
  • 27. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006; 91(12): 4753-61[DOI][PubMed]
  • 28. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48(4): 634-42[DOI][PubMed]
  • 29. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol. 2004; 41(6): 943-9[DOI][PubMed]
  • 30. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. 2006; 30(1): 13-7[DOI][PubMed]
  • 31. Diamanti-Kandarakis E, Christakou CD. Insulin Resistance in PCOS. 2009; [DOI]
  • 32. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol. 2014; 6(4): 199-206[DOI][PubMed]
  • 33. Awartani KA, Cheung AP. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can. 2002; 24(5): 393-401[PubMed]
  • 34. Goessling W, Massaro JM, Vasan RS, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterol J. 2008; 135(6): 1935-44
  • 35. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007; 53(4): 686-92[DOI][PubMed]
  • 36. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18): 2867-71[PubMed]
  • 37. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3): 745-50[PubMed]
  • 38. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis. 2001; 21(1): 71-80[PubMed]
  • 39. Jamali R. Non-Alcoholic Fatty Liver Disease. 2013;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader